tPA Modulation of the Blood–Brain Barrier: A Unifying Explanation for the Pleiotropic Effects of tPA in the CNS

 

 Buy Article Permissions and Reprints

Abstract

The plasminogen activation (PA) system is best known for its role in fibrinolysis. However, it has also been shown to regulate many nonfibrinolytic functions in the central nervous system (CNS). In particular, tissue-type plasminogen activator (tPA) is reported to have pleiotropic activities in the CNS, regulating events such as neuronal plasticity, excitotoxicity, and cerebrovascular barrier integrity, whereas urokinase-type plasminogen activator is mainly associated with tissue remodeling and cell migration. It has been suggested that the role tPA plays in controlling barrier integrity may provide a unifying mechanism for the reported diverse, and often opposing, functions ascribed to tPA in the CNS. Here we will review the possibility that the pleiotropic effects reported for tPA in physiologic and pathologic processes in the CNS may be a consequence of its role in the neurovascular unit in regulation of cerebrovascular responses and subsequently parenchymal homeostasis. We propose that this might offer an explanation for the ongoing debate regarding the neurotoxic versus neuroprotective roles of tPA.

• References

• 1 Collen D. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology (Am Soc Hematol Educ Program) 2001; •••: 1-9
  PubMedGoogle Scholar
• 2 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 (24) 1581-1587
  CrossrefPubMedGoogle Scholar
• 3 Li J, Yu L, Gu X , et al. Tissue plasminogen activator regulates Purkinje neuron development and survival. Proc Natl Acad Sci U S A 2013; 110 (26) E2410-E2419
  CrossrefPubMedGoogle Scholar
• 4 Seeds NW, Basham ME, Ferguson JE. Absence of tissue plasminogen activator gene or activity impairs mouse cerebellar motor learning. J Neurosci 2003; 23 (19) 7368-7375
  CrossrefPubMedGoogle Scholar
• 5 Minor K, Phillips J, Seeds NW. Tissue plasminogen activator promotes axonal outgrowth on CNS myelin after conditioned injury. J Neurochem 2009; 109 (3) 706-715
  CrossrefPubMedGoogle Scholar
• 6 Seeds NW, Siconolfi LB, Haffke SP. Neuronal extracellular proteases facilitate cell migration, axonal growth, and pathfinding. Cell Tissue Res 1997; 290 (2) 367-370
  CrossrefPubMedGoogle Scholar
• 7 Park L, Gallo EF, Anrather J , et al. Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci USA 2008; 105 (3) 1073-1078
  CrossrefPubMedGoogle Scholar
• 8 Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377 (6547): 340-344
  CrossrefPubMedGoogle Scholar
• 9 Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996; 384 (6605): 123-124
  PubMedGoogle Scholar
• 10 Nicole O, Docagne F, Ali C , et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7 (1) 59-64
  CrossrefPubMedGoogle Scholar
• 11 Echeverry R, Wu J, Haile WB, Guzman J, Yepes M. Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J Clin Invest 2010; 120 (6) 2194-2205
  CrossrefPubMedGoogle Scholar
• 12 Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17 (2) 543-552
  CrossrefPubMedGoogle Scholar
• 13 Rogove AD, Tsirka SE. Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr Biol 1998; 8 (1) 19-25
  CrossrefPubMedGoogle Scholar
• 14 Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112 (10) 1533-1540
  CrossrefPubMedGoogle Scholar
• 15 Su EJ, Fredriksson L, Geyer M , et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14 (7) 731-737
  CrossrefPubMedGoogle Scholar
• 16 Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 2012; 119 (20) 4752-4761
  CrossrefPubMedGoogle Scholar
• 17 Lemarchant S, Docagne F, Emery E, Vivien D, Ali C, Rubio M. tPA in the injured central nervous system: different scenarios starring the same actor?. Neuropharmacology 2012; 62 (2) 749-756
  CrossrefPubMedGoogle Scholar
• 18 Su EJ, Fredriksson L, Schielke GP, Eriksson U, Lawrence DA. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost 2009; 7 (Suppl. 01) 155-158
  CrossrefPubMedGoogle Scholar
• 19 Chevilley A, Lesept F, Lenoir S, Ali C, Parcq J, Vivien D. Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. Front Cell Neurosci 2015; 9: 415
  PubMedGoogle Scholar
• 20 Fredriksson L, Stevenson TK, Su EJ , et al. Identification of a neurovascular signaling pathway regulating seizures in mice. Ann Clin Transl Neurol 2015; 2 (7) 722-738
  CrossrefPubMedGoogle Scholar
• 21 Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57 (2) 173-185
  CrossrefPubMedGoogle Scholar
• 22 Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5 (5) 347-360
  CrossrefPubMedGoogle Scholar
• 23 Armulik A, Genové G, Mäe M , et al. Pericytes regulate the blood-brain barrier. Nature 2010; 468 (7323): 557-561
  CrossrefPubMedGoogle Scholar
• 24 Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7 (1) 41-53
  CrossrefPubMedGoogle Scholar
• 25 Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007; 10 (11) 1369-1376
  CrossrefPubMedGoogle Scholar
• 26 Parri R, Crunelli V. An astrocyte bridge from synapse to blood flow. Nat Neurosci 2003; 6 (1) 5-6
  CrossrefPubMedGoogle Scholar
• 27 Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 1994; 91 (22) 10625-10629
  CrossrefPubMedGoogle Scholar
• 28 Leybaert L, Cabooter L, Braet K. Calcium signal communication between glial and vascular brain cells. Acta Neurol Belg 2004; 104 (2) 51-56
  PubMedGoogle Scholar
• 29 Wu F, Wu J, Nicholson AD , et al. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci 2012; 32 (29) 9848-9858
  CrossrefPubMedGoogle Scholar
• 30 Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A 2005; 102 (2) 443-448
  CrossrefPubMedGoogle Scholar
• 31 Parcq J, Bertrand T, Montagne A , et al. Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ 2012; 19 (12) 1983-1991
  CrossrefPubMedGoogle Scholar
• 32 Hawkins RA. The blood-brain barrier and glutamate. Am J Clin Nutr 2009; 90 (3) 867S-874S
  CrossrefPubMedGoogle Scholar
• 33 Stobart JL, Anderson CM. Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front Cell Neurosci 2013; 7: 38
  PubMedGoogle Scholar
• 34 Zlokovic BV, Wang L, Sun N , et al. Expression of tissue plasminogen activator in cerebral capillaries: possible fibrinolytic function of the blood-brain barrier. Neurosurgery 1995; 37 (5) 955-961
  CrossrefPubMedGoogle Scholar
• 35 Huber D, Cramer EM, Kaufmann JE , et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002; 99 (10) 3637-3645
  CrossrefPubMedGoogle Scholar
• 36 Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361 (6411): 453-457
  CrossrefPubMedGoogle Scholar
• 37 Salles FJ, Strickland S. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 2002; 22 (6) 2125-2134
  CrossrefPubMedGoogle Scholar
• 38 Docagne F, Nicole O, Marti HH, MacKenzie ET, Buisson A, Vivien D. Transforming growth factor-beta1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J 1999; 13 (11) 1315-1324
  CrossrefPubMedGoogle Scholar
• 39 Sappino AP, Madani R, Huarte J , et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92 (2) 679-685
  CrossrefPubMedGoogle Scholar
• 40 Yu H, Schleuning WD, Michl M, Liberatore G, Tan SS, Medcalf RL. Control elements between -9.5 and −3.0 kb in the human tissue-type plasminogen activator gene promoter direct spatial and inducible expression to the murine brain. Eur J Neurosci 2001; 14 (5) 799-808
  CrossrefPubMedGoogle Scholar
• 41 Louessard M, Lacroix A, Martineau M , et al. Tissue plasminogen activator expression is restricted to subsets of excitatory pyramidal glutamatergic neurons. Mol Neurobiol 2015; DOI: 10.1007/s12035-015-9432-7.
  PubMedGoogle Scholar
• 42 Teesalu T, Kulla A, Simisker A , et al. Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost 2004; 92 (2) 358-368
  Article in Thieme ConnectPubMedGoogle Scholar
• 43 Gualandris A, Jones TE, Strickland S, Tsirka SE. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci 1996; 16 (7) 2220-2225
  CrossrefPubMedGoogle Scholar
• 44 Lochner JE, Honigman LS, Grant WF , et al. Activity-dependent release of tissue plasminogen activator from the dendritic spines of hippocampal neurons revealed by live-cell imaging. J Neurobiol 2006; 66 (6) 564-577
  CrossrefPubMedGoogle Scholar
• 45 Cauli B, Tong XK, Rancillac A , et al. Cortical GABA interneurons in neurovascular coupling: relays for subcortical vasoactive pathways. J Neurosci 2004; 24 (41) 8940-8949
  CrossrefPubMedGoogle Scholar
• 46 Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol (1985) 2006; 100 (3) 1059-1064
  CrossrefPubMedGoogle Scholar
• 47 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88 (4) 1346-1353
  CrossrefPubMedGoogle Scholar
• 48 Schrimpf SP, Bleiker AJ, Brecevic L , et al. Human neuroserpin (PI12): cDNA cloning and chromosomal localization to 3q26. Genomics 1997; 40 (1) 55-62
  CrossrefPubMedGoogle Scholar
• 49 Yamamoto M, Sawaya R, Mohanam S , et al. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res 1994; 54 (13) 3329-3332
  PubMedGoogle Scholar
• 50 Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999; 94 (12) 4177-4185
  CrossrefPubMedGoogle Scholar
• 51 Masos T, Miskin R. mRNAs encoding urokinase-type plasminogen activator and plasminogen activator inhibitor-1 are elevated in the mouse brain following kainate-mediated excitation. Brain Res Mol Brain Res 1997; 47 (1–2) 157-169
  CrossrefPubMedGoogle Scholar
• 52 Osterwalder T, Cinelli P, Baici A , et al. The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem 1998; 273 (4) 2312-2321
  CrossrefPubMedGoogle Scholar
• 53 Osterwalder T, Contartese J, Stoeckli ET, Kuhn TB, Sonderegger P. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J 1996; 15 (12) 2944-2953
  CrossrefPubMedGoogle Scholar
• 54 Hastings GA, Coleman TA, Haudenschild CC , et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997; 272 (52) 33062-33067
  CrossrefPubMedGoogle Scholar
• 55 Yepes M, Lawrence DA. Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost 2004; 91 (3) 457-464
  Article in Thieme ConnectPubMedGoogle Scholar
• 56 Wu J, Echeverry R, Guzman J, Yepes M. Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition. Am J Pathol 2010; 177 (5) 2576-2584
  CrossrefPubMedGoogle Scholar
• 57 Lee TW, Coates LC, Birch NP. Neuroserpin regulates N-cadherin-mediated cell adhesion independently of its activity as an inhibitor of tissue plasminogen activator. J Neurosci Res 2008; 86 (6) 1243-1253
  CrossrefPubMedGoogle Scholar
• 58 Lee TW, Tsang VW, Birch NP. Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system. Front Cell Neurosci 2015; 9: 396
  PubMedGoogle Scholar
• 59 Wang X, Lee SR, Arai K , et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9 (10) 1313-1317
  CrossrefPubMedGoogle Scholar
• 60 Cheng T, Petraglia AL, Li Z , et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12 (11) 1278-1285
  CrossrefPubMedGoogle Scholar
• 61 Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood 2015; 125 (19) 2898-2907
  CrossrefPubMedGoogle Scholar
• 62 Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A 2006; 103 (17) 6735-6740
  CrossrefPubMedGoogle Scholar
• 63 Pang PT, Teng HK, Zaitsev E , et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306 (5695): 487-491
  CrossrefPubMedGoogle Scholar
• 64 Fredriksson L, Li H, Fieber C, Li X, Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 2004; 23 (19) 3793-3802
  CrossrefPubMedGoogle Scholar
• 65 Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1992; 89 (16) 7427-7431
  CrossrefPubMedGoogle Scholar
• 66 Herz J. LRP: a bright beacon at the blood-brain barrier. J Clin Invest 2003; 112 (10) 1483-1485
  CrossrefPubMedGoogle Scholar
• 67 Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22 (9) 3352-3358
  CrossrefPubMedGoogle Scholar
• 68 Correa F, Gauberti M, Parcq J , et al. Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med 2011; 208 (6) 1229-1242
  CrossrefPubMedGoogle Scholar
• 69 Carmeliet P, Schoonjans L, Kieckens L , et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368 (6470): 419-424
  CrossrefPubMedGoogle Scholar
• 70 Yepes M. Tissue-type plasminogen activator is a neuroprotectant in the central nervous system. Front Cell Neurosci 2015; 9: 304
  PubMedGoogle Scholar
• 71 Szabo R, Samson AL, Lawrence DA, Medcalf RL, Bugge TH. Passenger mutations and aberrant gene expression in congenic tissue plasminogen activator-deficient mouse strains. J Thromb Haemost 2016; DOI: 10.1111/jth.13338.
  PubMedGoogle Scholar
• 72 Friedman GC, Seeds NW. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res 1994; 81 (1) 41-49
  CrossrefPubMedGoogle Scholar
• 73 Krystosek A, Seeds NW. Plasminogen activator release at the neuronal growth cone. Science 1981; 213 (4515): 1532-1534
  CrossrefPubMedGoogle Scholar
• 74 Lee SH, Ko HM, Kwon KJ , et al. tPA regulates neurite outgrowth by phosphorylation of LRP5/6 in neural progenitor cells. Mol Neurobiol 2014; 49 (1) 199-215
  CrossrefPubMedGoogle Scholar
• 75 Seeds NW, Basham ME, Haffke SP. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci U S A 1999; 96 (24) 14118-14123
  CrossrefPubMedGoogle Scholar
• 76 Stefanitsch C, Lawrence A-LE, Olverling A, Nilsson I, Fredriksson L. tPA deficiency in mice leads to rearrangement in the cerebrovascular tree and cerebroventricular malformations. Front Cell Neurosci 2015; 9: 456
  PubMedGoogle Scholar
• 77 Fredriksson L, Nilsson I, Su EJ , et al. Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. Am J Pathol 2012; 180 (3) 1136-1144
  CrossrefPubMedGoogle Scholar
• 78 Chai F, Coates H. Otolaryngological manifestations of ligneous conjunctivitis. Int J Pediatr Otorhinolaryngol 2003; 67 (2) 189-194
  CrossrefPubMedGoogle Scholar
• 79 Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001; 294 (5544): 1030-1038
  CrossrefPubMedGoogle Scholar
• 80 Frey U, Müller M, Kuhl D. A different form of long-lasting potentiation revealed in tissue plasminogen activator mutant mice. J Neurosci 1996; 16 (6) 2057-2063
  CrossrefPubMedGoogle Scholar
• 81 Huang YY, Bach ME, Lipp HP , et al. Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A 1996; 93 (16) 8699-8704
  CrossrefPubMedGoogle Scholar
• 82 Pawlak R, Nagai N, Urano T , et al. Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice. Neuroscience 2002; 113 (4) 995-1001
  CrossrefPubMedGoogle Scholar
• 83 Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995; 270 (5244): 1992-1994
  CrossrefPubMedGoogle Scholar
• 84 Müller CM, Griesinger CB. Tissue plasminogen activator mediates reverse occlusion plasticity in visual cortex. Nat Neurosci 1998; 1 (1) 47-53
  CrossrefPubMedGoogle Scholar
• 85 Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998; 21 (4) 813-825
  CrossrefPubMedGoogle Scholar
• 86 Madani R, Hulo S, Toni N , et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 1999; 18 (11) 3007-3012
  CrossrefPubMedGoogle Scholar
• 87 Zhuo M, Holtzman DM, Li Y , et al. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 2000; 20 (2) 542-549
  CrossrefPubMedGoogle Scholar
• 88 Blau CW, Cowley TR, O'Sullivan J , et al. The age-related deficit in LTP is associated with changes in perfusion and blood-brain barrier permeability. Neurobiol Aging 2012; 33 (5) 1005.e23-1005.e35
  CrossrefPubMedGoogle Scholar
• 89 Hsu TM, Kanoski SE. Blood-brain barrier disruption: mechanistic links between Western diet consumption and dementia. Front Aging Neurosci 2014; 6: 88
  PubMedGoogle Scholar
• 90 Takano T, Tian GF, Peng W , et al. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 2006; 9 (2) 260-267
  CrossrefPubMedGoogle Scholar
• 91 Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 1994; 144 (5) 855-861
  PubMedGoogle Scholar
• 92 Cipolla MJ, Lessov N, Clark WM, Haley Jr EC. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke 2000; 31 (4) 940-945
  CrossrefPubMedGoogle Scholar
• 93 Nassar T, Akkawi S, Shina A , et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 2004; 103 (3) 897-902
  CrossrefPubMedGoogle Scholar
• 94 Hill RA, Tong L, Yuan P, Murikinati S, Gupta S, Grutzendler J. Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes. Neuron 2015; 87 (1) 95-110
  CrossrefPubMedGoogle Scholar
• 95 An J, Haile WB, Wu F, Torre E, Yepes M. Tissue-type plasminogen activator mediates neuroglial coupling in the central nervous system. Neuroscience 2014; 257: 41-48
  CrossrefPubMedGoogle Scholar
• 96 Li B, Freeman RD. Neurometabolic coupling between neural activity, glucose, and lactate in activated visual cortex. J Neurochem 2015; 135 (4) 742-754
  CrossrefPubMedGoogle Scholar
• 97 Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33 (11) 2711-2717
  CrossrefPubMedGoogle Scholar
• 98 Zhang Z, Zhang L, Yepes M , et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002; 106 (6) 740-745
  CrossrefPubMedGoogle Scholar
• 99 Yao Y, Tsirka SE. Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood-brain barrier disruption. J Cell Sci 2011; 124 (Pt 9): 1486-1495
  CrossrefPubMedGoogle Scholar
• 100 Fredriksson L, Ehnman M, Fieber C, Eriksson U. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J Biol Chem 2005; 280 (29) 26856-26862
  CrossrefPubMedGoogle Scholar
• 101 Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012; 165 (1) 75-89
  CrossrefPubMedGoogle Scholar
• 102 Roger VL, Go AS, Lloyd-Jones DM , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 2012; 125 (1) e2-e220
  CrossrefPubMedGoogle Scholar
• 103 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257 (6) 2912-2919
  PubMedGoogle Scholar
• 104 Verheijen JH, Caspers MP, Chang GT, de Munk GA, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5 (13) 3525-3530
  CrossrefPubMedGoogle Scholar
• 105 Weimar W, Stibbe J, van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2 (8254): 1018-1020
  PubMedGoogle Scholar
• 106 Tsirka SE. Clinical implications of the involvement of tPA in neuronal cell death. J Mol Med (Berl) 1997; 75 (5) 341-347
  CrossrefPubMedGoogle Scholar
• 107 Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4 (2) 228-231
  CrossrefPubMedGoogle Scholar
• 108 del Zoppo GJ. tPA: a neuron buster, too?. Nat Med 1998; 4 (2) 148-150
  CrossrefPubMedGoogle Scholar
• 109 Mori T, Wang X, Kline AE , et al. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport 2001; 12 (18) 4117-4120
  CrossrefPubMedGoogle Scholar
• 110 Tanne D, Kasner SE, Demchuk AM , et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105 (14) 1679-1685
  CrossrefPubMedGoogle Scholar
• 111 Hacke W, Donnan G, Fieschi C , et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363 (9411): 768-774
  CrossrefPubMedGoogle Scholar
• 112 Hill MD, Buchan AM ; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172 (10) 1307-1312
  CrossrefPubMedGoogle Scholar
• 113 Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007; 24 (1) 1-10
  PubMedGoogle Scholar
• 114 Kleindorfer D, de los Rios La Rosa F, Khatri P, Kissela B, Mackey J, Adeoye O. Temporal trends in acute stroke management. Stroke 2013; 44 (6) (Suppl. 01) S129-S131
  CrossrefPubMedGoogle Scholar
• 115 Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA 2015; 313 (14) 1451-1462
  CrossrefPubMedGoogle Scholar
• 116 Ahmed N, Wahlgren N, Grond M , et al; SITS investigators. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9 (9) 866-874
  CrossrefPubMedGoogle Scholar
• 117 Wardlaw JM, Murray V, Berge E , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379 (9834): 2364-2372
  CrossrefPubMedGoogle Scholar
• 118 Saver JL, Fonarow GC, Smith EE , et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013; 309 (23) 2480-2488
  CrossrefPubMedGoogle Scholar
• 119 Emberson J, Lees KR, Lyden P , et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384 (9958): 1929-1935
  CrossrefPubMedGoogle Scholar
• 120 Yepes M, Sandkvist M, Wong MK , et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96 (2) 569-576
  CrossrefPubMedGoogle Scholar
• 121 Cinelli P, Madani R, Tsuzuki N , et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 2001; 18 (5) 443-457
  CrossrefPubMedGoogle Scholar
• 122 Tabrizi P, Wang L, Seeds N , et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 1999; 19 (11) 2801-2806
  CrossrefPubMedGoogle Scholar
• 123 Matys T, Strickland S. Tissue plasminogen activator and NMDA receptor cleavage. Nat Med 2003; 9 (4) 371-372 , author reply 372–373
  CrossrefPubMedGoogle Scholar
• 124 Samson AL, Nevin ST, Croucher D , et al. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem 2008; 107 (4) 1091-1101
  PubMedGoogle Scholar
• 125 Kidwell CS, Latour L, Saver JL , et al; UCLA Thrombolysis Investigators. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008; 25 (4) 338-343
  CrossrefPubMedGoogle Scholar
• 126 Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence?. J Cereb Blood Flow Metab 2012; 32 (7) 1207-1221
  CrossrefPubMedGoogle Scholar
• 127 Bardehle S, Rafalski VA, Akassoglou K. Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface. Front Cell Neurosci 2015; 9: 354
  PubMedGoogle Scholar
• 128 Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20 (12) 1681-1689
  CrossrefPubMedGoogle Scholar
• 129 Copin JC, Merlani P, Sugawara T, Chan PH, Gasche Y. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol 2008; 213 (1) 196-201
  CrossrefPubMedGoogle Scholar
• 130 Zhao BQ, Wang S, Kim HY , et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12 (4) 441-445
  CrossrefPubMedGoogle Scholar
• 131 Copin JC, Bengualid DJ, Da Silva RF, Kargiotis O, Schaller K, Gasche Y. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse. Eur J Neurosci 2011; 34 (7) 1085-1092
  CrossrefPubMedGoogle Scholar
• 132 Rodríguez-González R, Blanco M, Rodríguez-Yáñez M, Moldes O, Castillo J, Sobrino T. Platelet derived growth factor-CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator. Atherosclerosis 2013; 226 (1) 165-171
  CrossrefPubMedGoogle Scholar
• 133 Chatterjee S, Chakraborty A, Weinberg I , et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014; 311 (23) 2414-2421
  CrossrefPubMedGoogle Scholar
• 134 Gurwitz JH, Gore JM, Goldberg RJ , et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998; 129 (8) 597-604
  CrossrefPubMedGoogle Scholar
• 135 Turner RJ, Vink R. Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion injury following acute ischemic stroke in rats. Neuroscience 2012; 220: 1-10
  CrossrefPubMedGoogle Scholar
• 136 Su EJ, Fredriksson L, Kanzawa M , et al. Imatinib treatment reduces brain injury in a murine model of traumatic brain injury. Front Cell Neurosci 2015; 9: 385
  PubMedGoogle Scholar
• 137 Lewandowski SA, Nilsson I, Fredriksson L , et al. Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration. Acta Neuropathol 2016; 131 (3) 453-464
  CrossrefPubMedGoogle Scholar
• 138 Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 2010; 6 (7) 393-403
  CrossrefPubMedGoogle Scholar
• 139 Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99 (18) 2440-2444
  CrossrefPubMedGoogle Scholar
• 140 Matsuoka Y, Kitamura Y, Taniguchi T. Induction of plasminogen in rat hippocampal pyramidal neurons by kainic acid. Neurosci Lett 1998; 252 (2) 119-122
  CrossrefPubMedGoogle Scholar
• 141 Palmer AM, Marion DW, Botscheller ML, Swedlow PE, Styren SD, DeKosky ST. Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J Neurochem 1993; 61 (6) 2015-2024
  CrossrefPubMedGoogle Scholar
• 142 Armstead WM, Nassar T, Akkawi S , et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 2006; 9 (9) 1150-1155
  CrossrefPubMedGoogle Scholar
• 143 Armstead WM, Kiessling JW, Riley J, Cines DB, Higazi AA. tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res 2011; 33 (7) 726-733
  CrossrefPubMedGoogle Scholar
• 144 Sashindranath M, Samson AL, Downes CE , et al. Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation. Lab Invest 2011; 91 (7) 1079-1091
  CrossrefPubMedGoogle Scholar
• 145 Sashindranath M, Sales E, Daglas M , et al. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 2012; 135 (Pt 11): 3251-3264
  CrossrefPubMedGoogle Scholar
• 146 Orth K, Willnow T, Herz J, Gething MJ, Sambrook J. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator. J Biol Chem 1994; 269 (33) 21117-21122
  PubMedGoogle Scholar
• 147 Ashcom JD, Tiller SE, Dickerson K, Cravens JL, Argraves WS, Strickland DK. The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin. J Cell Biol 1990; 110 (4) 1041-1048
  CrossrefPubMedGoogle Scholar
• 148 Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008; 88 (3) 887-918
  CrossrefPubMedGoogle Scholar
• 149 Yepes M, Sandkvist M, Coleman TA , et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 2002; 109 (12) 1571-1578
  CrossrefPubMedGoogle Scholar
• 150 Tan ML, Ng A, Pandher PS , et al. Tissue plasminogen activator does not alter development of acquired epilepsy. Epilepsia 2012; 53 (11) 1998-2004
  CrossrefPubMedGoogle Scholar
• 151 Hassanien SH, Awadalla MM, Saad AA, Aziz NAA. Tissue plasminogen activator in children with idiopathic and intractable epilepsies. J Pediatr Neurol 2010; 8 (2) 193-197
  Article in Thieme ConnectPubMedGoogle Scholar
• 152 Schuele SU, Lüders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008; 7 (6) 514-524
  CrossrefPubMedGoogle Scholar
• 153 Janigro D. Does leakage of the blood-brain barrier mediate epileptogenesis?. Epilepsy Curr 2007; 7 (4) 105-107
  CrossrefPubMedGoogle Scholar
• 154 Marchi N, Angelov L, Masaryk T , et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007; 48 (4) 732-742
  CrossrefPubMedGoogle Scholar
• 155 Friedman A, Kaufer D, Heinemann U. Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. Epilepsy Res 2009; 85 (2–3) 142-149
  CrossrefPubMedGoogle Scholar
• 156 Marchi N, Tierney W, Alexopoulos AV, Puvenna V, Granata T, Janigro D. The etiological role of blood-brain barrier dysfunction in seizure disorders. Cardiovasc Psychiatry Neurol 2011; 2011
  PubMedGoogle Scholar
• 157 Reddrop C, Moldrich RX, Beart PM , et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36 (6) 1241-1246
  CrossrefPubMedGoogle Scholar
• 158 Mayhan WG, Didion SP. Glutamate-induced disruption of the blood-brain barrier in rats. Role of nitric oxide. Stroke 1996; 27 (5) 965-969 , discussion 970
  CrossrefPubMedGoogle Scholar
• 159 Tian GF, Azmi H, Takano T , et al. An astrocytic basis of epilepsy. Nat Med 2005; 11 (9) 973-981
  CrossrefPubMedGoogle Scholar